Payment overview · 2025
General Payments
$988.94
56 reported records · 19 companies
Healthcare provider profile · identity verified
Sara P Moore
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CLINTON, SC · NPI 1093266520
Verified facts
What the public records show
CMS Open Payments records show Sara P Moore received $988.94 in general payments during 2025 across 56 reported records.
ABBVIE INC. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $199.50 | 20.2% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $192.61 | 19.5% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $158.27 | 16.0% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $71.04 | 7.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.68 | 6.1% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.44 | 4.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.13 | 3.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.51 | 2.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $27.03 | 2.7% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $26.02 | 2.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.37 | 2.3% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $21.72 | 2.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.52 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.85 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.70 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.03 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.52 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.52 | 1.4% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $13.48 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $988.94 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $184.23 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $169.72 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $140.64 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $111.77 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $110.59 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $102.21 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $99.55 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $96.34 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $60.68 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $33.55 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.78 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $27.03 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 238 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 234 | 63 |
| Lisinopril | Lisinopril | 174 | 51 |
| Tramadol Hcl | Tramadol Hcl | 149 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 41 |
| Gabapentin | Gabapentin | 141 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 42 |
| Omeprazole | Omeprazole | 130 | 40 |
| Metformin Hcl | Metformin Hcl | 125 | 32 |
| Losartan Potassium | Losartan Potassium | 114 | 29 |
| Famotidine | Famotidine | 108 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 28 |
| Furosemide | Furosemide | 102 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 21 |
| Trazodone Hcl | Trazodone Hcl | 94 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 17 |
| Azithromycin | Azithromycin | 69 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 19 |
| Prednisone | Prednisone | 66 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 18 |
| Lorazepam | Lorazepam | 64 | 17 |
| Pregabalin | Pregabalin | 63 | 11 |
| Jardiance | Empagliflozin | 60 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 17 |
| Ozempic | Semaglutide | 53 | 12 |
| Farxiga | Dapagliflozin Propanediol | 50 | 12 |
| Metformin Hcl Er | Metformin Hcl | 50 | 15 |
| Ibuprofen | Ibuprofen | 49 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | suppressed |
| Potassium Chloride | Potassium Chloride | 47 | 15 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Sertraline Hcl | Sertraline Hcl | 42 | 14 |
| Naproxen | Naproxen | 40 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 13 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Aripiprazole | Aripiprazole | 38 | 12 |
| Ondansetron Odt | Ondansetron | 38 | 20 |
| Diazepam | Diazepam | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 11 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Carvedilol | Carvedilol | 26 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 13 |
| Eliquis | Apixaban | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Simvastatin | Simvastatin | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $988.94 · 56 records | ABBVIE INC. | AIRSUPRA, AREXVY, ARISTADA, Auvelity, BREZTRI, CAPVAXIVE, Dyanavel XR, ENFLONSIA, FARXIGA, GARDASIL 9, JARDIANCE, Kerendia, Korlym, LEQVIO, LYBALVI, MOUNJARO, Ozempic, QULIPTA, Quviviq, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error